Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinosonism

被引:14
作者
Kirollos, C
Charlett, A
Bowes, SG
Purkiss, AG
ONeill, CJA
Weller, C
Dickins, J
Faulkner, G
Nicholson, PW
Hunt, WB
Dobbs, RJ
Dobbs, SM
机构
[1] HILLINGDON HOSP, UXBRIDGE UB8 3NN, MIDDX, ENGLAND
[2] UNIV UXBRIDGE, POSTGRAD & RES CTR, UXBRIDGE UB8 3NN, MIDDX, ENGLAND
[3] PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, STAT UNIT, LONDON NW9 5EQ, ENGLAND
[4] UNIV COLL & MIDDLESEX SCH MED, LONDON, ENGLAND
[5] UNIV HERTFORDSHIRE, HATFIELD, HERTS, ENGLAND
关键词
selegiline; parkinsonian; monotherapy; placebo; newly diagnosed elderly; objective assessment;
D O I
10.1007/s002280050062
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rationale: Poor specificity of face-value endpoints and the poor sensitivity of gross clinical examination may have militated against demonstrating prophylaxis by selegiline. Methods: Objective measures of the four cardinal signs were used as primary outcome criteria in a randomised, double-blind, placebo-controlled, parallel group study of selegiline monotherapy in 25 newly diagnosed elderly sufferers from idiopathic parkinsonism, stratified for sex and Hoehn and Yahr functional staging. Results: There was a significant interaction between time and nature of treatment with respect to rigidity. The effect of time during active treatment was highly significant: rigidity decreased by 1.3 % per week. The worsening of rigidity on placebo was not statistically significant. Neuronal rescue is a possible explanation for the long term, progressive improvement produced by selegiline. No significant treatment effect was seen on the other cardinal signs. However, there was a significant quadratic time trend for arousal on active treatment suggesting tolerance to this effect. Conclusion: The difference in time course between the psychostimulant and physical effects suggests more than one mode of action.
引用
收藏
页码:7 / 18
页数:12
相关论文
共 82 条
  • [1] OXYGEN FREE-RADICALS AND PARKINSONS-DISEASE
    ADAMS, JD
    ODUNZE, IN
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1991, 10 (02) : 161 - 169
  • [2] SELEGILINE IN DENOVO PARKINSONIAN-PATIENTS - THE FRENCH SELEGILINE MULTICENTER TRIAL (FSMT)
    ALLAIN, H
    COUGNARD, J
    NEUKIRCH, HC
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 : 73 - 78
  • [3] ALTMAN DG, 1991, PRACTICAL STAT MED R, P371
  • [4] [Anonymous], APPL STAT
  • [5] MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE
    ARMSTRONG, M
    DALY, AK
    CHOLERTON, S
    BATEMAN, DN
    IDLE, JR
    [J]. LANCET, 1992, 339 (8800) : 1017 - 1018
  • [6] BARBEAU A, 1985, LANCET, V2, P1213
  • [7] Beck A T, 1974, Mod Probl Pharmacopsychiatry, V7, P151
  • [8] INCREASED LIFE EXPECTANCY RESULTING FROM ADDITION OF L-DEPRENYL TO MADOPAR TREATMENT IN PARKINSONS-DISEASE - A LONGTERM STUDY
    BIRKMAYER, W
    KNOLL, J
    RIEDERER, P
    YOUDIM, MBH
    HARS, V
    MARTON, J
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1985, 64 (02) : 113 - 127
  • [9] OBJECTIVE OUTCOME CRITERIA IN TRIALS OF ANTI-PARKINSONIAN THERAPY IN THE ELDERLY - SENSITIVITY, SPECIFICITY AND RELIABILITY OF MEASURES OF BRADYKINESIA AND HYPOKINESIA
    BOWES, SG
    CLARK, PK
    CHARLETT, A
    ONEILL, CJA
    LEEMAN, AL
    WELLER, C
    NICHOLSON, PW
    DESHMUKH, AA
    DOBBS, SM
    DOBBS, RJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (03) : 295 - 304
  • [10] BOWES SG, 1992, SCAND J REHABIL MED, V24, P181